Previous 10 | Next 10 |
NEW YORK, April 13, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2023 financial results on Tuesday, May 9, 2023 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m....
2023-04-12 02:26:28 ET Summary The White House's announcement on drug price caps caused a significant drop in biopharma stocks during Q1 2023. The impact of drug pricing-related caps and pressure will likely be limited, and the industry is expected to adapt and find new revenue st...
2023-03-27 07:42:50 ET Royalty Pharma ( NASDAQ: RPRX ) has authorized the repurchase of up to $1B of the company’s Class A ordinary shares. The buyback program is valid through June 2027. Pablo Legorreta, Royalty Pharma’s founder and Chief Executive Offic...
Royalty Pharma’s founder and Chief Executive Officer, Pablo Legorreta, has also indicated that he intends to purchase up to an additional $50 million of the company’s Class A ordinary shares NEW YORK, March 27, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) tod...
2023-03-23 08:08:44 ET Summary Halvorsen's 13F portfolio value decreased from $21.66B to ~$19.98B this quarter. The number of positions decreased from 88 to 53. Viking Global increased Amazon and UnitedHealth while decreasing General Electric, Meta Platforms, and Boston Scientific...
2023-03-23 07:54:57 ET Royalty Pharma ( NASDAQ: RPRX ) has acquired PureTech Health’s ( NASDAQ: PRTC ) royalty interest in KarXT, the lead investigational product of Karuna Therapeutics ( NASDAQ: KRTX ), for up to $500M, according to a Thursday press rel...
Royalty Pharma has acquired an interest in PureTech’s royalty in Karuna Therapeutics’ KarXT; Royalty Pharma and PureTech will share in royalties above certain annual sales thresholds PureTech retains its current equity stake in Karuna in addition to milestone payments and 20...
Royalty Pharma has acquired an interest in PureTech’s royalty in Karuna Therapeutics’ KarXT ; Royalty Pharma and PureTech will share in royalties above certain annual sales thresholds. PureTech retains its current equity stake in Karuna in addition to milesto...
2023-03-15 08:33:16 ET Royalty Pharma ( NASDAQ: RPRX ) said on Wednesday that it is raising its 2023 guidance after having received a $475M accelerated milestone payment from Pfizer. The payment follows an approval by the U.S. Food and Drug Administration of the company's ...
Royalty Pharma now expects 2023 Adjusted Cash Receipts ( 1) (non-GAAP) to be between $2,850 million and $2,950 million, excluding contributions from future transactions NEW YORK, March 15, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that ...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, July 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2024 financial results on Thursday, August 8, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 ...
NEW YORK, July 17, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2024 of $0.21 per Class A ordinary share. The dividend will be paid on September 13, 2024, to shareholders of record at the...